A Double-Blind, Randomized-Withdawal, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Human Plasma-Derived C1-Esterase Inhibitor as add-on Standard of care for the treatment of Refractory antibody
|Effective start/end date||5/1/17 → 5/30/23|
- CSL BEHRING GMBH
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.